<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mosley, Mary</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Modest, Dominik</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Impact of First-Line Therapy on Selection of Second-Line Therapy in FIRE-3 Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">16-16</style></pages><abstract><style  face="normal" font="default" size="100%">The influence of the drug combination used for first-line therapy on the selection and duration of the second-line therapy in patients with metastatic colorectal cancer (mCRC) was the objective of a post hoc analysis in the ongoing 5-FU, Folinic Acid and Irinotecan (FOLFIRI) Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment Colorectal Cancer trial [FIRE-3]. This article discusses the effect of first-line therapy on overall survival (OS) and the selection of subsequent treatment, and the effect of second-line therapy on OS [Modest D et al. Ann Oncol. 2014 (abstr O-0018)].</style></abstract><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>